Initially, we found that ATV at the doses of 20, 40 and 80 mg/(kg·day) led to significantly reduced TC and VLDL-c levels, while ATV at the doses of 40 and 80 mg/(kg·day) exhibited markedly decreased TG, LDL-c, ApoB, CETP and RBP4 levels along with elevated HDL-c and ApoAl levels in T2DM rats, highlighting the significance of the capability of using high-ATV doses to ameliorate blood lipid metabolism. The gene discussed is RBP4; the disease is type 2 diabetes mellitus.